{
  "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5",
  "docSlug": "225408061c3ed04b028031d27cf2467f",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides",
  "authorId": "immix-biopharma",
  "authorName": "ImmixBio",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 56,
  "pageCount": 62,
  "prevPage": 55,
  "nextPage": 57,
  "slideType": "solution",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "The slide uses a mix of mechanism-of-action diagrams, clinical trial bar charts, and preclinical mouse model data to validate the therapeutic approach.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/56",
  "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5",
  "deckJsonHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5.json",
  "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-56",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.5,
        "y": 0.15
      },
      "kind": "chart",
      "text": "Clinical trial results for Ulcerative Colitis and Crohn's Disease",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9e45cd8d-48cc-4da9-bdb1-7a088eb5b67f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.12,
        "x": 0.85,
        "y": 0.55
      },
      "kind": "chart",
      "text": "Mouse model inflammation score reduction",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4de7db90-de23-4b06-aed7-f72500ab7cc9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.3,
        "x": 0.5,
        "y": 0.45
      },
      "kind": "diagram",
      "text": "Mechanism of action showing GLUT1 targeting and immune cell inhibition",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a575e7f0-47cd-4275-b1b6-372e663eb570",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.25,
        "x": 0.05,
        "y": 0.035
      },
      "kind": "image",
      "text": "iMX-120 molecular structure diagram",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0f3cc370-e0ac-44b9-b991-ecee09deaa84",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.3,
        "x": 0.02,
        "y": 0.18
      },
      "kind": "paragraph",
      "text": "iMX-120 is a Tissue-Specific Biologic™ with Immune Normalization Technology encapsulating anti-inflammatory poly-kinase inhibitors (polyphenols) with proprietary targeting (GLUT1/ confidential targets) selectively silencing disease-causing inflammatory bowel immune cells.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "76385673-4fd8-4483-96e7-bf474d99d549",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.95,
        "x": 0.02,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Source: Adapted from Marzo et al, Lang et al, Alzahrani et al, Macintyre et al, Renaudin et al.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9474ac9d-42b8-4820-b5f2-05c01e532001",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "IMX-120 GLUT1 Biomarker-targeted for Inflammatory Bowel Disease",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f4f30aad-dd75-4315-9eca-fcac3785d0c8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "Mechanism of Action",
      "slug": null,
      "matchId": "0aba45fc-c9f6-4810-8ab1-0540d9ff232d",
      "evidence": "Visual representation of drug interaction with biological targets",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 62,
      "from": 35,
      "beatId": "676eee44-bd9e-41af-b9af-35da1fc6b1d6",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "The document outlines the market opportunity, competitive landscape, and future plans for NXC-201 and other pipeline assets.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}